RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer

Current targeted cancer therapies are largely guided by mutations of a single gene, which overlooks concurrent genomic alterations. Here, we show that RNASEH2B, RB1, and BRCA2, three closely located genes on chromosome 13q, are frequently deleted in prostate cancer individually or jointly. Loss of R...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Chenkui, Tsujino, Takuya, Takai, Tomoaki, Gui, Fu, Tsutsumi, Takeshi, Sztupinszki, Zsofia, Wang, Zengjun, Azuma, Haruhito, Szallasi, Zoltan, Mouw, Kent W., Zou, Lee, Kibel, Adam S., Jia, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856618/
https://www.ncbi.nlm.nih.gov/pubmed/35179959
http://dx.doi.org/10.1126/sciadv.abl9794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856618/
https://www.ncbi.nlm.nih.gov/pubmed/35179959
http://dx.doi.org/10.1126/sciadv.abl9794

Ejemplares similares